Postpartum anxiety statistics: how often it shows up, how often we miss it

She was five weeks out, awake at 3 a.m. again, not because the baby needed her but because she needed to check the bassinet one more time. Heart racing. A loop of images she could not shut off: the baby not breathing, herself dropping the baby on the stairs. At the six-week visit she told me she was "not depressed, just worried all the time." She was right. The PHQ-9 was mild. The GAD-7 was not.

Postpartum anxiety is not a softer version of postpartum depression. It is a different presentation that often runs alongside depression, sometimes instead of it, and frequently without a formal diagnosis. In clinic I hear intrusive worry and hypervigilance more often than the flat sadness people expect after a baby. The research literature has been slower to catch that reality.

This article gathers prevalence numbers that separate postpartum anxiety from depression, screening data that show where the system still looks mainly for sadness, overlap rates when both appear together, OCD-spectrum presentations that scare women out of disclosing, and the treatment-access gap that leaves most perinatal mental health conditions unaddressed.

Measure	Estimate	Source
Anxiety symptoms, 1-24 weeks postpartum	15.0%	Dennis et al., 2017
Any anxiety disorder, 1-24 weeks postpartum	9.9%	Dennis et al., 2017
Generalized anxiety disorder, 1-24 weeks	5.7%	Dennis et al., 2017
U.S. PRAMS anxiety symptoms (IL/MD)	18.0%	Farr et al., 2014
U.S. postpartum depressive symptoms	13.2%	CDC PRAMS, 2018 (Bauman et al., 2020)
Comorbid anxiety + mild/severe depression symptoms	8.2%	Falah-Hassani et al., 2017

Source: Dennis et al., British Journal of Psychiatry, 2017; Farr et al., Journal of Women's Health, 2014; Bauman et al., MMWR, 2020; Falah-Hassani et al., Psychological Medicine, 2017.

Weeks postpartum	Cumulative incidence
4	5%
8	6%
12	7%
16	8%
26	9%

Source: Fairbrother et al., Journal of Clinical Psychiatry, 2021. DSM-5 diagnostic interviews in a weighted British Columbia cohort; 9% cumulative incidence of new OCD by 6 months postpartum.

How common is postpartum anxiety

The cleanest international estimate for postpartum anxiety symptoms still comes from the 2017 systematic review and meta-analysis by Cindy-Lee Dennis, Karen Falah-Hassani, and Rahman Shiri in the British Journal of Psychiatry. They pooled 102 studies covering 221,974 women from 34 countries. For the first 1-24 weeks after birth, self-reported anxiety symptoms sat at 15.0% (95% CI 13.7-16.4). When diagnostic interviews rather than symptom screens were used, any anxiety disorder affected 9.9% of women in that same window, and generalized anxiety disorder specifically affected 5.7%.

Those rates stay high across the postpartum year. The same meta-analysis put anxiety symptoms at 17.8% in the first 4 weeks, 14.9% at 5-12 weeks, 15.0% across the full 1-24 week band, and 14.8% beyond 24 weeks. The early peak is clinically familiar: sleep is most fragmented, feeding is still being established, and the body has not settled.

A broader diagnostic lens raises the number further. In 2019, Emily Fawcett and colleagues published a multivariate Bayesian meta-analysis in the Journal of Clinical Psychiatry estimating that 20.7% of perinatal women (roughly 1 in 5) meet criteria for at least one anxiety disorder (95% highest density interval 16.7% to 25.4%). Individual disorders ranged from about 1.1% for posttraumatic stress disorder to 4.8% for specific phobia. Pregnant women were only modestly more susceptible than postpartum women, by about 3.1 percentage points. That is the figure I reach for when someone asks for one clean number.

U.S. population-based data tell a similar story. Sherry Farr and colleagues at the CDC, using 2009-2010 Pregnancy Risk Assessment Monitoring System (PRAMS) data from Illinois and Maryland, found that 18.0% of 4,451 postpartum women reported anxiety symptoms on validated screening questions. Not a specialty-clinic sample. Mothers surveyed after a live birth, and nearly one in five screened positive.

Set that next to depression and the comparison stops being theoretical. CDC research shows about 1 in 8 women with a recent live birth report postpartum depressive symptoms: 13.2% across 31 PRAMS sites in the agency's 2018 Vital Signs analysis. Anxiety symptoms in the Farr PRAMS analysis and the Dennis meta-analysis land at or above that range. On symptom measures, postpartum anxiety is at least as common as postpartum depression.

The World Health Organization still frames the global burden mainly around depression: about 10% of pregnant women and 13% of women who have just given birth experience a mental disorder, primarily depression. Those figures do not fully capture anxiety-only presentations.

Distinct from depression, often alongside it

The clinical distinction matters because treatment plans change when anxiety is the primary problem. A mother with panic, constant body scanning, and sleep that never comes even when the baby sleeps is not the same patient as one with anhedonia and slowed thinking. Our review of postpartum depression statistics covers the depression side; this section is the shared middle.

Comorbidity is common. Falah-Hassani, Shiri, and Dennis, writing in the Journal of Affective Disorders in 2016, followed 522 women near Vancouver through 1, 4, and 8 weeks postpartum. Using an Edinburgh Postnatal Depression Scale score of 10 or higher plus a State-Trait Anxiety Inventory state score of 40 or higher at the same time point, they found comorbid depressive and anxiety symptoms in 13.1% of women during the first 8 weeks.

Their 2017 meta-analysis in Psychological Medicine widened the lens. Across 66 studies and 162,120 women, co-occurring anxiety symptoms and mild-to-severe depressive symptoms between 1 and 24 weeks postpartum affected 8.2% (95% CI 6.5-9.9). Comorbid anxiety with moderate-to-severe depression was 5.7%. A clinical diagnosis of comorbid anxiety and depression was present in 4.2%. Antenatally, the self-report comorbidity rate was 9.5%.

A 2025 update by Ou and colleagues, pooling 122 articles and more than 560,000 women, put global co-morbid anxiety and depression at about 9% across the perinatal period, with roughly 8% postpartum and 9% in pregnancy. The overlap has not shrunk as awareness of perinatal depression has grown.

The Farr CDC analysis adds a useful U.S. detail: among the 18.0% of women with postpartum anxiety symptoms, 35% also reported depressive symptoms, for an overall comorbidity rate of 6.3% in that two-state PRAMS sample. Most women with postpartum anxiety in that study did not also screen positive for depression. Depression-only screening misses a large group. Our overview of anxiety and depression statistics in women shows the same pattern across the reproductive years: anxiety often precedes or outlasts depression.

Comorbidity measure	Rate	Window / sample
Anxiety + depression symptoms (EPDS ≥10 and STAI ≥40)	13.1%	First 8 weeks; Falah-Hassani et al., 2016
Anxiety + mild/severe depression symptoms	8.2%	1-24 weeks postpartum; Falah-Hassani et al., 2017
Anxiety + moderate/severe depression symptoms	5.7%	1-24 weeks postpartum; Falah-Hassani et al., 2017
Clinical diagnosis of comorbid anxiety and depression	4.2%	Postpartum diagnostic studies; Falah-Hassani et al., 2017
Anxiety with concurrent depressive symptoms	35% of those with anxiety (6.3% overall)	PRAMS IL/MD; Farr et al., 2014
Global co-morbid anxiety and depression, postpartum	~8%	Ou et al., 2025 meta-analysis

Source: Falah-Hassani et al., Journal of Affective Disorders, 2016 and Psychological Medicine, 2017; Farr et al., Journal of Women's Health, 2014; Ou et al., Psychological Medicine, 2025.

Screening coverage gaps

ACOG has been clear that anxiety belongs in the screen. Committee Opinion No. 757 (2018) recommends that obstetric care providers screen patients at least once during the perinatal period for depression and anxiety symptoms using a standardized, validated tool, with a full mood assessment at the comprehensive postpartum visit. ACOG's 2023 Clinical Practice Guideline No. 4 expands that further, covering depression, anxiety and related disorders, bipolar disorder, suicidality, and postpartum psychosis, and supports repeated screening across pregnancy and postpartum rather than a single checkbox.

Practice has not fully caught the policy. The CDC's 2018 PRAMS Vital Signs analysis found that among women who attended a postpartum visit (90.1% of respondents), 87.4% reported that a provider asked about depression. That still leaves one in eight not asked postpartum, and during prenatal care only 79.1% reported being asked. One in five was not asked at all. Site variation was extreme: postpartum depression inquiry ranged from 50.7% in Puerto Rico to 96.2% in Vermont; prenatal inquiry from 51.3% in Puerto Rico to 90.7% in Alaska.

Here is the quieter problem: those PRAMS questions ask whether a provider inquired about feeling "down or depressed." They do not measure whether anyone asked about worry, panic, intrusive thoughts, or compulsive checking. A system can post a 90% depression-screen rate and still miss anxiety-primary presentations. The tools exist: the Edinburgh Postnatal Depression Scale anxiety subscale, the GAD-7, the Perinatal Anxiety Screening Scale. None of that helps if the workflow only drops a PHQ-2 into the chart. Screening without a referral path is theater. Depression-only screening in a population where anxiety is at least as prevalent is also incomplete.

Who gets asked varies. In the CDC analysis, younger mothers and those on Medicaid were more likely to report being asked about depression prenatally than older, privately insured mothers. That pattern may reflect risk-targeted rather than universal screening. ACOG recommends universal screening. Many clinics still do risk-targeted screening under time pressure.

Postpartum OCD-spectrum presentations

If there is one postpartum anxiety presentation that is both underdiagnosed and clinically urgent to get right, it is OCD-spectrum illness, especially intrusive thoughts of infant-related harm. These thoughts are ego-dystonic: the mother finds them horrifying, not desirable. The opposite is the delusional conviction seen in postpartum psychosis. Mislabeling OCD as psychosis can lead to unnecessary separation from the infant. Missing psychosis is dangerous for different reasons. Both errors happen when clinicians are not trained to ask.

The prevalence numbers have been revised upward as methods improved. Nichole Fairbrother and colleagues, publishing in the Journal of Clinical Psychiatry in 2021, followed English-speaking women in British Columbia with DSM-5 diagnostic interviews that explicitly asked about perinatal-specific obsessions and compulsions. Weighted postpartum period prevalence of OCD was 16.9% (95% CI 14.0-20.2). Average postpartum point prevalence was 7.0%. Point prevalence rose through late pregnancy and the early postpartum, peaking near 8.7% around 8 weeks, then gradually declining. Cumulative incidence of new OCD diagnoses reached about 9% by 6 months postpartum.

Those estimates are higher than older meta-analyses that used DSM-IV criteria and rarely asked about infant-related harm thoughts. Fairbrother's group attributes the gap to both the diagnostic criteria change and the inclusion of perinatal-specific questions. Women often do not map "unwanted violent thoughts" onto a standard OCD checklist item about harm unless someone names the baby in the question.

Common contents include contamination fears focused on the infant, checking breathing through the night, avoidance of knives or bath time, and intrusive sexual or aggressive images the mother would never act on. Shame keeps disclosure late. A mother who thinks she is a danger to her child will not volunteer that information unless she trusts the response will be clinical, not punitive. Postpartum psychosis remains rare (classically on the order of 1 to 2 per 1,000 births) and is a psychiatric emergency. OCD is not rare. Conflating the two harms both groups.

Treatment access

Detection is only useful if treatment follows, and treatment is where the numbers look worst.

The 2023 American Psychiatric Association and CDC Foundation white paper on perinatal mental and substance use disorders states that upwards of 75% of pregnant people affected by mental health symptoms remain untreated. That figure aggregates depression, anxiety, and related conditions; anxiety is not carved out as better served. The same document notes that anxiety disorders are often overlooked in pregnancy and postpartum even though they are common.

The economic case is not subtle. Luca and colleagues, writing in the American Journal of Public Health in 2020, estimated that untreated perinatal mood and anxiety disorders cost about $14 billion for the 2017 U.S. birth cohort from conception through five years postpartum, or roughly $31,800 per affected mother-child dyad. Mothers bore about 65% of those costs. Those models include anxiety alongside depression; leaving anxiety out of the clinical pathway does not leave it out of the cost pathway.

Access barriers are structural. Maternity care deserts limit who can even reach a postpartum visit, a problem we map in our review of maternity care deserts and provider shortages. Mental health shortages are worse in the same counties. Medications compatible with breastfeeding exist and are underused because clinicians and patients both overestimate risk relative to untreated illness. CBT and exposure-based treatments for OCD work, but only if someone trained in them is available.

There has been progress: state perinatal psychiatry access programs modeled on Massachusetts MCPAP for Moms, clearer ACOG screening mandates, Medicaid postpartum coverage extensions. None of that yet shows a treatment rate to be proud of. If anxiety is the main symptom, say so and ask for a GAD-7 or full perinatal assessment, not only a depression screen. If intrusive harm thoughts are present, say they are unwanted and distressing. Our period calculator and ovulation calculator can help interpret irregular postpartum cycles, but they are not a substitute for mental health care.

What the numbers mean clinically

Three practical conclusions follow from the data.

First, prevalence justifies routine dual screening. When roughly 15% of postpartum women have significant anxiety symptoms, about 10% meet criteria for an anxiety disorder in the early months, and about 1 in 5 perinatal women meet criteria for some anxiety disorder across the broader window, anxiety cannot be an optional add-on to a depression workflow.

Second, comorbidity is high enough that a positive depression screen should trigger an anxiety assessment, and the reverse. The Falah-Hassani estimate of 8.2% comorbidity on symptom measures, and the Farr finding that 35% of women with anxiety also had depressive symptoms, both argue against single-construct screening.

Third, OCD-spectrum symptoms need explicit questions. Fairbrother's 7% average postpartum point prevalence and 9% six-month cumulative incidence of new OCD are not numbers to leave to chance disclosure. Ask about unwanted thoughts of harm, contamination, and checking. Document the difference from psychosis.

The mother who checked the bassinet at 3 a.m. improved with a selective serotonin reuptake inhibitor compatible with lactation, brief CBT focused on intolerance of uncertainty, and one honest conversation that her thoughts were symptoms, not character. She needed someone to name the problem correctly on the first visit. That is a systems problem as much as a clinical one.

Maternal mental health still sits inside the larger story of preventable maternal harm. Our analysis of preventable maternal mortality is the right companion read when the question expands from prevalence to deaths that follow untreated psychiatric illness.

Frequently asked questions about postpartum anxiety

How common is postpartum anxiety compared with postpartum depression?

Self-reported postpartum anxiety symptoms affect about 15.0% of women at 1-24 weeks after birth, per Dennis and colleagues' 2017 meta-analysis. CDC PRAMS data put postpartum depressive symptoms at 13.2% in 2018. On symptom measures, anxiety is at least as common as depression. A 2019 meta-analysis estimated that 20.7% of perinatal women meet criteria for at least one anxiety disorder.

Can you have postpartum anxiety without depression?

Yes. In the CDC PRAMS analysis by Farr and colleagues, 18.0% of postpartum women had anxiety symptoms, and only 35% of that group also reported depressive symptoms. Most women with anxiety in that sample did not meet the study's depression threshold. Depression-only screening will miss anxiety-primary cases.

How often do postpartum anxiety and depression occur together?

A 2017 meta-analysis by Falah-Hassani, Shiri, and Dennis estimated that 8.2% of women have co-occurring anxiety and mild-to-severe depressive symptoms between 1 and 24 weeks postpartum. In a Canadian cohort, comorbidity reached 13.1% in the first 8 weeks when both symptom thresholds were met at the same visit.

How common is postpartum OCD?

In Fairbrother and colleagues' 2021 DSM-5 study, average postpartum point prevalence of OCD was about 7.0%, peaking near 8.7% around 8 weeks after birth. Period prevalence across the postpartum follow-up was 16.9%, and about 9% of women developed new OCD by 6 months. Older estimates that did not ask about infant-related obsessions were substantially lower.

Do providers routinely screen for postpartum anxiety?

ACOG recommends screening for depression and anxiety with validated tools, including at the postpartum visit. CDC PRAMS data show 87.4% of women who attended a postpartum visit were asked about depression, but that question does not measure anxiety-specific screening. One in eight were not asked about depression postpartum, and one in five were not asked prenatally.

What share of perinatal mental health conditions go untreated?

The 2023 APA/CDC Foundation white paper reports that upwards of 75% of pregnant people with mental health symptoms remain untreated. Untreated perinatal mood and anxiety disorders were estimated to cost about $14 billion for the 2017 U.S. birth cohort, or roughly $31,800 per affected mother-child pair, according to Luca and colleagues in the American Journal of Public Health.